An analysis of data from over 3.5 million patients found comparable clinical outcomes among patients who initiated generics vs those who were treated with brand-name drugs for chronic conditions such as diabetes, hypertension, osteoporosis, depression and anxiety.
Genetic variants mimicking effect of ATP citrate lyase inhibitors, statins lower LDL-C in same way.
The Food and Drug Administration (FDA) has approved a new generic version of Diovan (Novartis) that does not contain N-nitrosodimethylamine (NDMA) or N-nitrosodiethylamine (NDEA), 2 potentially carcinogenic impurities identified in several recalled valsartan products.
A systematic review and meta-analysis published in the American Journal of Cardiovascular Drugs compared the safety and efficacy of prasugrel and ticagrelor in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).
Alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, was found to be both safe and effective in reducing low-density lipoprotein cholesterol (LDL-C) in patients with heterozygous familial hypercholesterolemia (HeFH) across different age groups, according to a post-hoc analysis.
For patients with heart failure with reduced ejection fraction (HFrEF), treatment with sacubitril/valsartan may aid in reducing the requirement for loop diuretics compared with enalapril, according to the results of a follow-up analysis of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF) trial.
Baxter announced the availability of ready-to-use Eptifibatide Injection in a flexible container.
PDL BioPharma has announced the availability of an authorized generic version of Tekturna (aliskiren hemifumarate; Noden Pharma).
Models developed for individuals in whom aspirin is being considered for primary prevention of CVD.
Primary end point occurred in lower percentage of patients in 180-day period; difference not significant
